This study is a randomized double blind clinical trials will be conducted on 62 asthmatic patients (intervention and control group, each 31 cases) the inclusion criteria included patients with mild persistent to moderate persistent asthma (grade 2 and 3 criteria, the severity of asthma) and exclusion criteria included pregnancy, people which currently taking statin drugs, history of sensitivity to statin drugs, history of hospitalization during the last month, smokers, history of hepatitis or active liver disease, myopathy or myositis. intervention Group treated with atorvastatin tablets 40 mg oral daily dose for 8 weeks and control group during this period will receive placebo. At the onset of the study after obtaining informed consent, the standard questionnaire of asthma control test (ACT ) will be filled out by patients followed by a spirometry. A blood sample to measure the number of peripheral blood eosinophil, serum low-density lipoprotein, high density lipoprotein, total cholesterol and triglycerides are taken from the patient. Four weeks after the treatment of asthma, control questionnaire will be complete again and re-matched patients with possible side effects of the drugs and asthma control level. Finally, after eight weeks of treatment, again filling the questionnaire asthma control and Spirometry is taken from patients. blood samples to determine changes in the number peripheral blood eosinophil, serum total cholesterol and triglyceride is taken. The expected primary outcome was improve the degree of control of clinical asthma symptoms based on the asthma controlled test (ACT) Expected secondary outcomes include to improve pulmonary volumes [percent of forced expiratory volume in one second (% 1FEV) and percentage of vital capacity (% FVC)] and decrease the number of peripheral blood eosinophil. Maintenance treatment of asthmatic patients are not altered. At the begining and the end of the study to assess drug compliance of the patients, Serum cholesterol and TG measurement tests will be done.